Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

IF 1.6 4区医学 Q2 Medicine

Acta Clinica Belgica Pub Date : 2023-04-01 DOI:10.1080/17843286.2022.2076791

Shun-Yu Kong, Jiao-Jiao Song, Yao-Qi Jin, Man-Jun Deng, Jing-Xin Yan

{"title":"Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.","authors":"Shun-Yu Kong, Jiao-Jiao Song, Yao-Qi Jin, Man-Jun Deng, Jing-Xin Yan","doi":"10.1080/17843286.2022.2076791","DOIUrl":null,"url":null,"abstract":"Background: We carried out a systematic review and meta-analysis to assess the safety and effectiveness of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (uHCC).Methods: Eligible studies were searched by MEDLINE, the Cochrane Library, Embase, and Web of Science from January 1995 to January 2022, investigating eligible literature comparing HAIC and TACE for patients with HCC. The main outcome measures included progression-free survival (PFS), overall survival (OS), adverse events (AEs), objective response rate (ORR), and diseases control rate (DCR).Results: Eight literature and 1028 patients were enrolled in this meta-analysis. The pooled PFS, OS, ORR, and DCR were HR = 0.89 (95% CI, 0.81-0.98), HR = 0.84 (95% CI, 0.75-0.93), OR = 2.77 (95% CI, 2.01-3.80), and OR = 4.64 (95% CI, 2.40-8.99), respectively. The adverse events of HAIC were lower than TACE.Conclusion: Our meta-analysis revealed that HAIC can achieve a better effect and survival benefits than TACE in patients with uHCC.","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":"78 2","pages":"171-179"},"PeriodicalIF":1.6000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Clinica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17843286.2022.2076791","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 4

Abstract

Background: We carried out a systematic review and meta-analysis to assess the safety and effectiveness of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (uHCC).

Methods: Eligible studies were searched by MEDLINE, the Cochrane Library, Embase, and Web of Science from January 1995 to January 2022, investigating eligible literature comparing HAIC and TACE for patients with HCC. The main outcome measures included progression-free survival (PFS), overall survival (OS), adverse events (AEs), objective response rate (ORR), and diseases control rate (DCR).

Results: Eight literature and 1028 patients were enrolled in this meta-analysis. The pooled PFS, OS, ORR, and DCR were HR = 0.89 (95% CI, 0.81-0.98), HR = 0.84 (95% CI, 0.75-0.93), OR = 2.77 (95% CI, 2.01-3.80), and OR = 4.64 (95% CI, 2.40-8.99), respectively. The adverse events of HAIC were lower than TACE.

Conclusion: Our meta-analysis revealed that HAIC can achieve a better effect and survival benefits than TACE in patients with uHCC.

查看原文本刊更多论文

肝动脉输注化疗与经动脉化疗栓塞治疗不可切除肝癌:一项系统回顾和荟萃分析。

背景:我们进行了一项系统回顾和荟萃分析，以评估肝动脉输注化疗(HAIC)与经动脉化疗栓塞(TACE)对不可切除肝细胞癌(uHCC)患者的安全性和有效性。方法:从1995年1月至2022年1月，通过MEDLINE、Cochrane图书馆、Embase和Web of Science检索符合条件的研究，调查比较HAIC和TACE治疗HCC患者的符合条件的文献。主要结局指标包括无进展生存期(PFS)、总生存期(OS)、不良事件(ae)、客观缓解率(ORR)和疾病控制率(DCR)。结果:8篇文献和1028例患者纳入本荟萃分析。合并PFS、OS、ORR和DCR分别为HR = 0.89 (95% CI, 0.81-0.98)、HR = 0.84 (95% CI, 0.75-0.93)、OR = 2.77 (95% CI, 2.01-3.80)和OR = 4.64 (95% CI, 2.40-8.99)。HAIC组的不良事件低于TACE组。结论:我们的荟萃分析显示，在uHCC患者中，HAIC比TACE可以获得更好的疗效和生存获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Clinica Belgica 医学-医学：内科

CiteScore

2.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine primarily publishes papers on clinical medicine, clinical chemistry, pathology and molecular biology, provided they describe results which contribute to our understanding of clinical problems or describe new methods applicable to clinical investigation. Readership includes physicians, pathologists, pharmacists and physicians working in non-academic and academic hospitals, practicing internal medicine and its subspecialties.